강스템바이오텍

217730KOSDAQ기초 의약물질 제조업

49.8 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but Revenue is on a declining trend. Plunged 34.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Kansstem Biotech, established in 2010, specializes in developing and manufacturing stem cell therapies, with core businesses in stem cell treatments and cosmetics. The stem cell division focuses on therapies for conditions like atopic dermatitis and rheumatoid arthritis, while the cosmetics division sells stem cell-derived products through online channels. The company also develops new drugs based on exosome technology for wound healing and hair loss.

Number of Employees

172people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

3.35Industry Average 1.741.0Point

1.9x industry avg (risky)

ROE

-18.65Industry Average -6.033.5Point

3.1x industry avg (excellent)

Debt Ratio

5.98Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -29.2% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
강스템바이오텍, 바이오USA 참가…"빅파마 협력 모델 가시화"
강스템바이오텍의 바이오USA 참가로 빅파마와의 협력 모델 가시화 및 임상 진행 소식이 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
강스템바이오텍, 오가노이드 첫 고객사 내방…반복매출화 검증대
강스템바이오텍의 오가노이드 사업이 고객사 방문을 통해 성공적인 반복매출 가능성을 입증하며 긍정적인 전망을 제시했다.

Detailed Momentum

52-week position3.0Point

52w lower range (37%)

Current 2,460Won52-week high 4,61552-week low 1,171

1-month return0.0Point

1m -34.22% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-06-02
Neutral분기보고서 (2026.03)2026-05-14